Contineum Therapeutics, Inc. (CTNM) Stock Price & Analysis

Contineum Therapeutics, Inc. (CTNM) closed at USD 8.4 on Thursday, October 22, 2026, up 0.54% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 8.35; the Oct 22, 2026 session ranged USD 8.12–8.75 on volume of 498,752 shares. Market capitalization is $315.83M, with a 52-week range of USD 6.73–17.79 (NMS). Source: Nexqual, retrieved October 23, 2026 at 10:34 UTC.

Also available as compact Markdown for AI agents: nexqual.com/CTNM.md

Key facts (CTNM)

• Insider open-market sales, last ~7 months: 10 Form 4 filings, $1.2M; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 2.13 on a 1–5 scale) (8 analysts), mean target USD 22.14 (range 14–30).
• Total return with dividends: 1Y -24.5% vs S&P 500 +14.9%; 5Y -45.5% vs S&P 500 +80.3%.
• Next earnings: 2026-10-29, EPS estimate USD -0.45, revenue estimate $0K.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CTNM)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (CTNM)

P/B 1.3x · FCF yield -16.93% · Earnings yield -18.22%

Insider sales (SEC Form 4, open-market, last ~7 months) (CTNM)

10 of 10 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (CTNM)

Consensus Buy (mean 2.13 on a 1–5 scale), 8 analysts; mean target USD 22.14 (low 14, high 30).

Rating changes, last 120 days:

Total return (dividends reinvested) (CTNM)

CTNM suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 5, 2026.

CTNM company outlook (results filed Jul 30, 2026)

• “With a projected cash runway that extends through mid-2029, which is approximately one year past the estimated completion of our IPF trial, we are maintaining a disciplined approach to capital allocation." Stengone continued, "We're grateful to Dan for his years of leadership, service and contributions in founding and helping build Contineum into the world-class organization it is today.”

Quoted word-for-word from the SEC 8-K results press release.

CTNM analyst estimates and revisions

CTNM options: expected move

Options price a move of about ±25.0% (±$2.10) by Nov 20, 2026, which includes earnings on Oct 29, 2026. Over the last 8 reports the stock moved ±7% on average.

30-day implied volatility 97.6% vs 153.8% realized over the last 30 trading days. Put/call ratio (volume) —. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 23, 2026 at 10:34 UTC)

Technical Analysis (CTNM)

Nexqual's technical model rates CTNM "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 10:34 UTC.

Analyst Ratings (CTNM)

Wall Street analysts rate CTNM "Buy" based on 8 analysts, with a mean price target of USD 22.14 (range USD 14–30), per Nexqual as of October 23, 2026 at 10:34 UTC.

Earnings (CTNM)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 10:34 UTC.

Financials & Fundamentals (CTNM)

Source: Nexqual, October 23, 2026 at 10:34 UTC.

Financial Health Score (CTNM)

Nexqual rates Contineum Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:34 UTC.

Ownership (CTNM)

Source: Nexqual, October 23, 2026 at 10:34 UTC.

Leadership (CTNM)

Contineum Therapeutics, Inc. is led by Carmine N. Stengone MBA, MS, President, CEO & Director, per Nexqual as of October 23, 2026 at 10:34 UTC.

Major Backers & Investors (CTNM)

Notable institutional backers of Contineum Therapeutics, Inc. include Montanova Capital LLC, Jupiter Topco LLC, Johnson & Johnson, according to Nexqual as of October 23, 2026 at 10:34 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 10:34 UTC.

From Contineum Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)

Key Strengths & Strategy (as disclosed to the SEC)

• We have built our current pipeline with the goal of minimizing clinical risk.
• Our collaboration provides a foundation for the development of PIPE-307 with access to J&J's robust R&D and commercialization capabilities, which we believe will allow us to achieve the full potential of PIPE-307.
• To that end, we have developed a selective calpain inhibitor which was recently moved into preclinical studies.

Partnerships

• We recognize that partnerships may provide a more prudent development path in certain cases to reduce costs and accelerate the delivery of effective therapies to market, as exemplified by our partnership with J&J.
• In February 2023, we entered into a license agreement with J&J, under which we granted J&J an exclusive, worldwide license to develop, manufacture and commercialize PIPE-307 in all indications ("J&J License Agreement").

Legal & Regulatory Risks (Item 1A, quoted)

• We currently have no products that are approved for commercial sale and may never be able to develop a marketable product.
• We may experience delays in initiating and successfully completing the clinical trials that we intend to conduct, including our current and planned clinical trials for PIPE-791.
• We may not be successful in our efforts to identify and develop additional drug candidates or identify additional indications. Due to our limited resources and access to capital, we must prioritize development of a limited number of drug candidates, the choice of which may prove to be wrong and adversely affect our business and prospects.
• We have and may continue to conduct future clinical trials outside of the United States. The FDA and other regulatory authorities or ethics committees may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business and financial condition.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:34 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt